Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Cellectis (CLLS) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $8.00 price target on the stock.
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]